New Brunswick, NJ, September 4, 2014 ― Rutgers Cancer Institute of New Jersey (CINJ) will host “Oncology Pipeline Update” on Tuesday, September 30 from 4:00 to 6:00 p.m. in CINJ’s Auditorium A and B, 195 Little Albany Street, New Brunswick.
The HealthCare Institute of New Jersey (HINJ) is an event co-sponsor.
This is the inaugural seminar in the Rutgers University – Industry Cancer Seminar Series, which is designed to foster collaboration and networking between Rutgers faculty and strategic industry partners.
The September 30 seminar will provide an update on drugs in the developmental pipeline at Bristol-Myers Squibb and current basic and clinical research projects at Rutgers, with the objective of initiating a dialogue for validating novel cancer therapeutics.
Forum speakers will be:
- Jim Cassidy, M.D., Ph.D., Vice President, Oncology Clinical and Translational Research, Bristol-Myers Squibb
- Howard L. Kaufman, M.D., FACS, Chief Surgical Officer and Associate Director for Clinical Sciences, Rutgers Cancer Institute of New Jersey and Professor of Surgery, Rutgers Robert Wood Johnson Medical School
- Edmund C. Lattime, Ph.D., Associate Director for Education and Training, Cancer Institute of New Jersey and Professor of Surgery, Robert Wood Johnson Medical School
- Janice Mehnert, M.D., Interim Director, Phase I and Developmental Therapeutics, Cancer Institute of New Jersey and Associate Professor of Medicine, Robert Wood Johnson Medical School
- Derek Sant’ Angelo, Ph.D., Division Chief, Developmental Biology, Associate Professor of Pediatrics, Robert Wood Johnson Medical School
The forum will be followed by a light reception.
Registration is not required. To access the event flyer, click here.